Simcere Pharmaceutical Group Limited has announced a new research collaboration with Stanford Medicine to explore a potential new treatment for idiopathic pulmonary fibrosis (IPF), a serious and life-threatening lung disease with limited treatment options.
The partnership aims to advance an exploratory research project focused on a novel molecule that could offer a new therapeutic approach for patients living with IPF. The collaboration represents another step in Simcere Pharmaceutical’s efforts to strengthen its innovation pipeline and address diseases with significant unmet medical needs.
Under the terms of the agreement, Simcere Pharmaceutical will provide funding for the exploratory research program. If the project achieves its research objectives, Simcere will obtain an exclusive license to the molecule and acquire full worldwide rights to any resulting product.
This arrangement allows Simcere to support early-stage scientific discovery while creating a pathway for future clinical development and commercialization.
The project will be conducted through collaboration with leading chemical biology laboratories at Stanford Medicine. The research will be led by Dr. Chaitan Khosla and Dr. Cui Bianxiao, both members of the Stanford Innovative Medicines Accelerator.
Dr. Khosla is a professor in Stanford University's Departments of Chemistry and Chemical Engineering, an institute scientist at the Sarafan ChEM-H Institute, and director of the Innovative Medicines Accelerator. He is also a member of several prestigious scientific organizations, including the U.S. National Academy of Sciences, the National Academy of Engineering, and the American Academy of Arts and Sciences. His work includes expertise in LYTAC-related technologies.
Dr. Cui Bianxiao is a professor in Stanford University's Department of Chemistry and a fellow at the Wu Tsai Neurosciences Institute. Her research focuses on fibrosis-related biological targets, and she has received multiple scientific honors, including the Barany Prize from the Biophysical Society and the NIH New Innovator Award.
Addressing a Serious Unmet Need in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis is a chronic and progressive lung disease characterized by scarring of lung tissue. Over time, the lungs become stiff and lose their ability to function properly, making breathing increasingly difficult.
The exact cause of IPF remains unknown. Current treatment options can help slow disease progression but cannot reverse existing lung damage. The disease is associated with poor outcomes, with a median survival time of approximately three years following diagnosis. The five-year survival rate is estimated to be between 20% and 40%.
Because of these challenges, there is a strong need for new therapies that can more effectively target the underlying disease process.
Simcere Highlights Commitment to Innovation
Commenting on the collaboration, Zhou Gaobo, Head of Investment at Simcere Pharmaceutical, said the project represents the second globally unique program to emerge from the company’s partnership with Stanford Medicine.
He noted that the continued collaboration reflects Simcere's move toward its "Innovation 2.0" strategy and supports the company's mission of "For Patients, For Life." He also expressed optimism about developing additional innovative therapies through the partnership to benefit patients worldwide.
Stanford Researchers See Opportunity for Breakthrough Treatment
Professor Chaitan Khosla emphasized the urgent need for more effective therapies for idiopathic pulmonary fibrosis.
He stated that highly specific treatments for IPF have remained a major unmet medical need for many years and expressed enthusiasm about working with Simcere to translate new discoveries from chemical biology into potential therapies.
Simcere Continues to Expand Its Innovation Pipeline
Simcere Pharmaceutical is a research-driven pharmaceutical company focused on developing innovative therapies across several key therapeutic areas, including neuroscience, oncology, autoimmune diseases, and infectious diseases.
The company operates the National Key Laboratory for the Development of Neurology and Oncology Drugs and continues to invest in areas where significant clinical needs remain unmet. Through a combination of internal research and external collaborations, Simcere has established partnerships with numerous biotechnology companies, academic institutions, and research organizations worldwide.
The new collaboration with Stanford Medicine adds another promising research program to Simcere’s growing portfolio of innovation-focused partnerships, with the potential to bring new treatment options to patients affected by idiopathic pulmonary fibrosis.